心肺超声在参麦注射液联合芪参益气滴丸治疗扩张型心肌病患者疗效评估中的应用效果

摘要
图/表
参考文献(17)
相关文章 (15)

全文: PDF (593 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨心肺超声在参麦注射液联合芪参益气滴丸治疗扩张型心肌病（DCM）患者疗效评估中的应用效果。方法选取2019年6月至2021年4月江西省人民医院收治的180例DCM患者作为研究对象，采用随机数字表法分为观察A组、观察B组及对照组，每组各60例。观察A组在常规治疗的基础上给予参麦注射液联合芪参益气滴丸治疗；观察B组在常规治疗的基础上给予芪参益气滴丸治疗；对照组给予常规治疗。比较三组患者治疗6个疗程后的临床疗效；同时比较治疗前后三组患者的各项心肺超声参数及肺超声B线积分。结果治疗6个疗程后，观察A组的治疗总有效率高于对照组与观察B组，差异有统计学意义（P＜0.05）。观察B组与对照组的治疗总有效率比较，差异无统计学意义（P＞0.05）。治疗后观察A组、观察B组患者的左心室收缩末期内径（LVESD）、左室舒张末期内径（LVEDD）、左心室后壁运动延迟时间（SPWMD）、心胸比例（CTR）和肺动脉收缩压（PASP）均低于对照组，左室射血分数（LVEF）高于对照组，且治疗后观察A组患者的LVESD、LVEDD、SPWMD、CTR、PASP均低于观察B组，LVEF高于观察B组，差异有统计学意义（P＜0.05）。治疗前，三组患者的肺超声B线积分比较，差异无统计学意义（P＞0.05）；治疗后，观察A组、观察B组患者的肺超声B线积分低于对照组，且观察A组患者的肺超声B线积分低于观察B组，差异有统计学意义（P＜0.05）。结论心肺超声能评价参麦注射液联合芪参益气滴丸治疗DCM患者的疗效。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	崔亮

关键词 ：心肺超声, 参麦注射液, 芪参益气滴丸, 扩张型心肌病, 治疗效果, 评估价值

Abstract：Objective To investigate the application effect of cardiopulmonary ultrasound in evaluating the curative effect of Shenmai Injection combined with Qishen Yiqi Dropping Pills on patients with dilated cardiomyopathy (DCM). Methods A total of 180 patients with DCM admitted to Jiangxi Provincial People′s Hospital from June 2019 to April 2021 were selected as the research objects, and they were divided into observation group A, observation group B, and control group according to the random number table method, with 60 patients in each group. Patients in observation group A were treated with Shenmai Injection combined with Qishen Yiqi Dropping Pills on the basis of conventional treatment. Patients in observation group B were treated with Qishen Yiqi Dropping Pills on the basis of conventional treatment, and patients in control group were given conventional treatment. The three groups were compared in terms of the clinical effect after 6 courses of treatment, the cardiopulmonary ultrasound parameters and lung ultrasound B-line scores before and after treatment. Results After 6 courses of treatment, the total treatment response rate in observation group A was higher than those in control group and observation group B, and the differences were statistically significant (P<0.05). There was no statistically significant difference in the total treatment response rate between observation group B and the control group (P>0.05). The left ventricular end systolic diameter (LVESD), left ventricular and diastolic diameter (LVEDD), septal-to-posterior wall motion delay (SPWMD), cardiothoracic ratio (CTR) and pulmonary artery systolic pressure (PASP) after treatment in observation group A and observation group B were lower than those in the control group, and left ventricular ejection fraction (LVEF) was higher than that in the control group, the LVESD, LVEDD, SPWMD, CTR and PASP in observation group A were lower than those in observation group B, and LVEF was higher than that in observation group B, the differences were statistically significant (P<0.05). There was no statistically significant difference in lung ultrasound B-line scores among the three groups before treatment (P>0.05). After treatment, the B-line score of observation group A and observation group B were lower than those of control group, and the B-line score of observation group A was lower than that of observation group B, the differences were statistically significant (P<0.05). Conclusion Cardiopulmonary ultrasound can be used to evaluate the curative effect of Shenmai Injection combined with Qishen Yiqi Dropping Pills on patients with DCM.

Key words： Cardiopulmonary ultrasound Shenmai Injection Qishen Yiqi Dropping Pills Dilated cardiomyopathy Curative effect Evaluation value

基金资助:江西省中医药管理局科技计划项目（2020A0086）

作者简介: 崔亮（1982-），女，湖南湘潭人，硕士，研究方向：心脏超声。

引用本文:

崔亮. 心肺超声在参麦注射液联合芪参益气滴丸治疗扩张型心肌病患者疗效评估中的应用效果[J]. 中国当代医药, 2022, 29(21): 9-13.
CUI Liang. Application effect of cardiopulmonary ultrasound in evaluating the curative effect of Shenmai Injection combined with Qishen Yiqi Dropping Pills on patients with dilated cardiomyopathy. 中国当代医药, 2022, 29(21): 9-13.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2022/V29/I21/9

[1]	郭小乐，王雪臣，李庆海.李庆海治疗扩张型心肌病经验[J].中国中医基础医学杂志，2021，27（3）：513-514，534.
[2]	翟玫，黄丽燕，王运红，等.扩张型心肌病合并心腔内血栓患者的临床特点分析[J].中国循环杂志，2021，36（6）：563-566.
[3]	边汝涛，王振涛.中医药治疗扩张型心肌病的研究进展[J].中西医结合心脑血管病杂志，2019，17（12）：1826-1828.
[4]	张洁，顾长斌，周皖舒.参麦注射液联合沙库巴曲缬沙坦对心力衰竭患者心功能、血液流变学的影响[J].湖北中医药大学学报，2021，23（3）：34-37.
[5]	张娟，许久军，张连珍，等.芪参益气滴丸对心力衰竭患者疗效及内皮功能、肾功能的调节机制[J].解放军医药杂志，2021，33（2）：89-92.
[6]	程康宁，任波.参麦注射液联合米力农治疗急性心力衰竭的疗效分析[J].中国现代医学杂志，2021，31（14）：92-96.
[7]	翟夏，董静，康启.芪参益气滴丸对慢性心力衰竭患者心功能的影响[J].实用临床医药杂志，2020，24（12）：32-34， 38.
[8]	Hunt SA，Baker DW，Chin MH，et al.ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adults[J].J Am Cardiol，2001，38（7）：2010-2113.
[9]	中华医学会心血管病学分会，中华心血管病杂志编辑委员会，中国心肌病诊断与治疗建议工作组.心肌病诊断与治疗建议[J].中华心血管病杂志，2007，35（1）：5-16.
[10]	王蔚文.临床疾病诊断与疗效判断标准[M].北京：科学技术文献出版社，2010：563.
[11]	吴琼，彭珑萍，董艺丹，等.扩心方治疗气阴两虚兼血瘀证扩张型心肌病患者的临床研究[J].中国中医急症，2021， 30（11）：1940-1943，1946.
[12]	徐伟丽，刘勇先，朱华强.左卡尼汀联合曲美他嗪治疗老年扩张型心肌病患者的效果观察[J].广西医学，2021，43（21）：2544-2548.
[13]	吉米丽汗·司马依，买买提明·努尔买买提，艾尼瓦尔·吾买尔，等.基于整合药理学研究参麦注射液治疗心力衰竭的生物作用机制[J].中国临床药理学杂志，2021，37（1）：75-77.
[14]	张倩，董玉江.人参养荣汤加减治疗扩张型心肌病的临证经验[J].中西医结合心脑血管病杂志，2021，19（16）：2862-2864.
[15]	徐伟丽，刘勇先，朱华强.左卡尼汀联合曲美他嗪治疗老年扩张型心肌病患者的效果观察[J].广西医学，2021，43（21）：2544-2548.
[16]	许丽君，张银妆，匡圆圆，等.血浆TSG-6水平与扩张型心肌病心力衰竭患者心功能、心肌纤维化及预后的相关性[J].中南大学学报（医学版），2021，46（7）：689-696..
[17]	李雅，魏佳明，李玉莹，等.益心泰有效组分对扩张型心肌病心力衰竭兔心肌组织CaN、SERCA2a mRNA及蛋白表达水平的影响研究[J].中国全科医学，2021，24（32）：4086-4093.